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ABSTRACT 
 
Evaluations of sub-national anti-retroviral therapy (ART) programmes’ performance are important to support 
regional programme planning and epidemic response. We constructed a four-year retrospective cohort of 
clients from 10 care and treatment clinics (CTC) in the Mbeya region of Tanzania using routinely collected 
data from patients initiating ART between January 1, 2008 and March 31, 2012. Our primary outcomes were 
mortality rate and lost to follow up. We calculated ART coverage based on regional prevalence estimates 
and used medical cards, drug registers and quarterly reports to assess data quality. We enrolled 17,813 
participants into the cohort. More patients initiated ART at WHO stages 3 (58.9%), and at CD4 cell counts 
between 50-199 cells/µl (56%). The proportion of patients initiating ARTs at a CD4 counts <50 cells/µl 
decreased from 40.7% in 2008 to 33.8% in 2012 (p-value <0.001). A total of 10,155 (57.0%) patients were 
lost to follow up (LTFU) during the 4 years of follow up; 59.2% were female. The overall mortality rate was 
17.8 per 1000 person years; the six-month mortality was 6.2 per 1000 person years. The risk of mortality for 
patients at WHO stage III and IV was more than twice as high (hazard ratio [HR] 2.15; 95% confidence 
interval [CI], 1.05-4.39 and HR 2.29; 95% CI, 1.39-6.37, respectively) as compared to stage I and II. Those 
patients initiating ART with CD4 cell count between 50 and 199 cells/µl had significantly lower hazard of 
death compared to those initiating ART with CD4 cells counts <50 cells/µl (HR 0.51, 95% CI 0.34-0.78). In 
conclusion, during the study, a high proportion of patients were lost to follow up, and the majority of them 
were female. Most patients initiated ARTs at lower CD4 count (<200 cells/mm3) and at WHO stages III and 
IV, and they had higher risk of mortality compared to those initiated at higher CD4 counts and WHO stage I 
and II. Emphasis needs to be placed on strategies of early diagnosis of HIV infection, prompt initiation of 
ART, and support for ART adherence to minimise lost to follow up.  
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INTRODUCTION 
 
Access to anti-retroviral therapy (ART) is rapidly 
expanding; at the end of 2010 an estimated 6.6 million 
people were receiving ART in low-income and middle-
income countries  (Gray et al., 2011). There is  increasing  
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pressure on national care and treatment programmes to 
diagnose, enrol and retain large numbers of people onto 
ART. Increasing coverage requires scaling up 
programmes across countries and decentralising the 
provision of care and treatment to lower level facilities. 
These sites, however, have limited capacity and 
resources, which may impact their effectiveness. Further, 
such programmes face considerable challenges caused 
by patients’ late presentation at treatment sites and high 
levels of attrition (Agu et al., 2010).  
The National HIV/AIDS Care and Treatment Plan for 
the Tanzanian mainland were launched in October 2003, 
and the actual implementation began in October 2004. 
Provision of ART was decentralised to regional and 
district hospitals in 2005 and to health centres starting in 
2007. By the end of 2009, Tanzania had approved 909 
facilities to provide care and treatment services, enabling 
more than 300 000 patients to access ART (NACP, 
2010). 
Although Tanzania’s national HIV prevalence is 5.6%, 
there are considerable regional disparities, with a HIV 
prevalence of 15.7% in Iringa Region and 9.2% in Mbeya 
Region (NACP, 2010). Care and treatment clinics (CTC) 
have been set up across the country, but there are 
regional differences in coverage, capacity and resources. 
The CTCs routinely collect data covering socio-
demographic and clinical characteristics and send reports 
to the National Care and Treatment database. Some 
clinics report at the individual level and others aggregate 
the data and report at the clinic level. Few studies have 
evaluated the CTC programmes based on their collection 
of routine data, and those that have focus on the national 
level (Somi et al., 2012). In this paper we present the 
results from a detailed evaluation of the routinely 
collected ART programme data from 10 public-sector 
CTCs using an electronic database in the Mbeya region 
in the Southern Highlands region of Tanzania. 
 
 
MATERIALS AND METHODS 
 
Study design 
 
We conducted a four-year retrospective cohort analysis to evaluate 
the CTC programme in Mbeya from January 1, 2008 to March 31, 
2012. We supplemented this with a small cross sectional study to 
review the quality and completeness of data collection at the CTCs 
and interpretation of national data to make region-specific estimates 
for the programme coverage. 
 
 
Study setting 
 
Mbeya is a highland region located in south-western Tanzania and 
borders Zambia and Malawi. It has a population of over 2 million 
people (Commission THEP, nd). Mbeya Region has the third 
highest prevalence in the country at 9.2%. It has 15 hospitals, 29 
health centres and 271 dispensaries. They are 49 CTCs in the 
region; 10 of these sites had active electronic databases and 
collected longitudinal data on all patients registered at the CTC 
since 2006.  Patient-level  data  from  these  10  clinics  formed  the  
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basis of this analysis. According to the 2007 national guidelines, 
patients were considered eligible for ART if they had WHO stage IV 
disease irrespective of CD4 cell count, WHO stage III with CD4 ≤ 
350 cells/μl or had CD4 ≤ 200 cells/μl regardless of clinical stage 
(Somi et al., 2011).  
 
 
Study population 
 
We included data for all patients ≥15 years old at the time of ART 
initiation who began ART at one of the 10 CTCs in Mbeya region 
from January 2008 to March 2013.  
 
 
Data collection 
 
We extracted data from the database to obtain estimates of the 
regional HIV prevalence stratified by age group. We calculated HIV 
care coverage by dividing the number of adults currently in care by 
the estimated total number of HIV-infected adults population at the 
regional level and ART coverage from the number currently on ART 
divided by the number in need of treatment. HIV prevalence in 
adults ≥50 years was estimated as the HIV prevalence in 15-to-49-
year-old adults divided by the factor of 1.7 (NACP report number 2, 
2010). 
We extracted data with the following variables: socio-
demographic information, weight, height, CD4 cell count, WHO 
stage and CD4 count at initiation. For patients’ final outcomes we 
extracted variables for last known status, classified as in care, dead 
or lost to follow up (which included transferred out, dead, stopped 
treatment, not attended for the last 3 months). 
We used a tool from the Ministry of Health and Social Welfare for 
the data quality assessment. We randomly sampled five of the 10 
clinics with electronic databases to verify data collection, storage 
and reporting at the service delivery level for data collected 
between January and June 2012. The tool is a checklist that 
compiles information pertaining to the number and quality of reports 
that have been collected and submitted to the national level. The 
checklist included documentation review, recounting reported 
results and cross-checking reported results with other data sources. 
We conducted verification checks between the patient medical 
dossiers such as standardized form (CTC2 cards) and the relevant 
registers including ART registers and quarterly reports. 
 
 
Data analysis 
 
We analysed the data using Stata version 12 (Stata Corp., College 
Station, Texas, USA). We used frequencies and percentages to 
describe categorical variables and median and interquartile ranges 
(IQR) to describe continuous variables. To investigate baseline 
predictor changes over time we performed Chi-squared tests for 
trend and displayed significant results graphically. We calculated 
unadjusted mortality rates with 95% confidence limits for each level 
of predictor variables to explore factors associated with mortality, 
including socio-demographic characteristics, weight, WHO stage 
and CD4 count on ART initiation. We fitted unadjusted and adjusted 
Cox proportional hazard regression models to control potential 
confounding factors associated with the outcome in crude analysis. 
 
 
Ethical consideration 
 
We received permission from the National AIDS Control 
Programme to use the data and obtained ethical clearance from the 
Kilimanjaro Christian Medical College research ethics committee. 
No contact with human subjects occurred. Patients were only 
identified by number to preserve  anonymity;  we  removed all  other  
 
 
 
 
personal identifiers from the dataset before analysis.  
 
 
RESULTS 
 
Overall an estimated 128,285 adults were living with 
HIV/AIDS in the region at the end of 2011. Of these, 
70,327 (54.8%) were enrolled in care and treatment 
programmes, and 43,084 (33.6%) were on ART (Figure 
1). A total of 17,813 patients had initiated ART in the 10 
clinics between January 1, 2008 and March 31, 2012 
(Table 1). The medium follow up time was three months 
IQR (1.0 to 7.3) months, accruing 25,958 person-years 
observations. Overall, 10,708 (60.1%) patients were 
female. The overall age distribution was similar across all 
years, with an overall median age of 37.0 (IQR 31.0 to 
44.0). Functional status at ART initiation improved over 
time, with more people working (92.8%), and fewer bed-
ridden (1.3%). The median baseline weight of patients 
initiating ART was 52 kg (range 46.0 to 59); nearly half 
(46.4%) weighed between 45 and 55 kg.  
Most people initiated ART at WHO stage 3 (58.9%) and 
with a CD4 cell count of between 50 and 199 cells/mm3 
(56.0%). Of the 17,813 that began ART during the study 
period, 10,155 (57.0%) were lost to follow up during the 4 
years  of  follow  up;  5,645 (31.7%) were lost to follow up  
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within one year. After four years only 7,608 (42.7%) 
remained in care. The proportion of patients initiating 
ART at a CD4 count of <200 cells/µl fell across the four 
year cohort (40.7 to 33.8%) while the proportion starting 
ART with a CD4 count of 200-349 cells/µl rose in the 
same period (16.4 to 26.1%, p<0.001) (Figure 2). 
Four hundred sixty-two (2.6%) of 17,813 patients 
initiating ART were known to have died within the follow 
up period, with an overall mortality rate of 17.8 per 1000 
person years (Table 2). The majority died within the first 
six month of treatment (6.2 per 1000 person years). 
Baseline WHO stage, CD4 count, weight, age and 
gender were predictors of mortality in bivariate analysis. 
After adjustment all factors except age remained 
independently and significantly associated with mortality 
(Table 3). We tested the proportional hazards assumption 
in the Cox regression model using the test of Schonfield, 
and there was no evidence against the proportional 
hazard assumption (global chi-square 21.65 for 16 
degree of freedom, p = 0.16) 
Missing data were common: 21.7% had missing 
variables for weight, 24.7% for functional status, 32.4% 
for marital status, 21.7% for CD4 count, and 98.7% for 
body mass index because most height was not 
documented in 78%. Age and WHO stage had fewer 
missing data (0.9% and 0.4%, respectively). 
 
 
128,285* HIV positive
70,327 (54.8%) registered at 
CTC sites across the Region
* Estimates taken from the regional prevalence of 9.2% multiplied by the estimated 
population of 15+ years
43,084 (61.3%) in need and 
receiving ARVs
27243(38.7%) in need and 
not receiving ARVs
57,957 (45.2%) not 
registered at CTC sites across 
the Region
Mortality rate of 17.8 per 
1000 person years
17,813 initiated treatment across 10 
study sites between 2008-2012
10,155 (57.0%) Lost to follow 
up within 4 year follow up
A
bs
tr
ac
te
d 
fr
om
 th
e 
Re
gi
on
al
 D
at
a 
se
t
A
bs
tr
ac
te
d 
fr
om
 
st
ud
y 
da
ta
 
 
Figure 1. Coverage of HIV services and ART, adults ≥15 years old, Mbeya region, 
Tanzania, 2011. 
 
 
 
DISCUSSION 
 
We found  that  after  four-years  of  observation,  57%  of  
patients who initiated ART in 10 clinics in a highly 
affected region of Tanzania were lost to follow up and 
only  42.7%  remained alive and in care. These data were 
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 Table 1. Baseline and socio-demographic characteristics of the study population. 
 
Parameter Total(N)  2008  2009  2010  2011  2012 
Number in study 17,813 %  4,824 %  4,965 %  3,672 %  3,178 %  1,178 % 
Female 10,708 (60.1)  2,925 (60.6)  2,958 (59.6)  2,175 (59.2)  1,896 (59.7)  753 (63.9) 
                  
Age in years                  
15-29 3,558 (20.2)  969 (20.4)  970 (19.6)  769 (21.1)  628 (19.9)  222 (18.9) 
30-39 7,206 (40.8)  1,967 (41.4)  2,022 (40.9)  1,479 (40.7)  1289 (40.9)  449 (38.3) 
40-49 4,435 (25.1)  1,191) (25.1  1,254 (25.3)  865 (23.8)  806 (25.6)  319 (27.9) 
50+ 2,455 (13.9)  622 (13.1)  695 (14.0)  525 (14.4)  430 (13.6)  183 (15.6) 
Missing 163 (0.9%)  75 (1.6)  24 (0.5)  34 (0.9)  25 (0.8)  5 (0.4) 
Median (IQR) 37.0 (31.0 – 44.0)  36 (31-44)  37 (31-44)  36 (30-44)  37 (31-44)  38 (31-45) 
            
Marital status                  
Single 1,940 (10.9)  132 (16.5)  578 (14.6)  562 (16.8)  488 (17.1)  179 (16.7) 
Married/cohabiting 7,099 (39.8)  482 (60.4)  2298 (57.9)  1917 (57.3)  1708 (59.8)  695 (64.7) 
Divorced/separated 1,080 (6.1)  72 (9.02)  373 (9.4)  330 (9.9)  240 (8.4)  66 (6.1) 
Widow 1,928 (16.0)  112 (14.0)  723 (18.2)  537 (16.1)  422 (14.8)  135 (12.6) 
Missing 5,770 (32.4)  4026 (83.5)  994 (20)  326 (8.9)  320 (10.1)  104 (8.8) 
                  
Functional status                  
Ambulatory 784 (5.9)  40 (4.8)  129 (2.8)  118 (3.2)  193 (6.1)  304 (25.9) 
Bedridden 177 (1.3)  18 (2.2)  30 (0.7)  80 (2.2)  45 (1.4)  4 (0.3) 
Working 12,449 (92.8)  780 (93.1)  4,406 (96.5)  3469 (94.6)  2927 (92.5)  867 (73.8) 
Missing 4,407 (24.7)  3,986 (82.6)  400 (8.1)  5 (0.1)  13 (0.4)  3 (0.3) 
                  
Weight (kg)                  
<45 3,017 (17.5)  908 (19.2)  887 (18.6)  573 (16.3)  492 (15.9)  157 (13.6) 
45-55 80,006 (46.4)  2,301 (48.7)  2218 (46.4)  1599 (45.6)  1343 (43.3)  5445 (47.3) 
>56 6,247 (36.2)  1,518 (32.1)  1673 (35.0)  1337 (38.1)  1265 (40.8)  454 (39.3) 
Median (IQR) 52.0 (46.0 – 59.0)  51.7 (46-58)  52(46-59)  53 (47-60)  53 (47-60)  54 (48-60) 
Missing 547 (3.07)  97 (2.0)  187 (3.8)  163 (4.4)  78 (2.3)  22 (1.9) 
                  
CD4 Cell count/µl                  
<50 2,682 (19.2)  768 (20.7)  779 (19.7)  539 (19.1)  441 (17.7)  155 (15.9) 
50-199 7,812 (56.0)  2,249 (60.7)  2275 (57.4)  1516 (53.9)  1240 (49.9)  532 (54.5) 
200-349 2,852 (20.5)  606 (16.4)  750 (18.9)  6119 (21.9)  648 (26.1)  229 (23.4) 
350-499 417 (2.9)  58 (1.6)  116 (2.9)  94 (3.3)  104 (4.2)  45 (4.6) 
>500 186 (1.3)  25 (0.7)  41 (1.0)  51 (1.8)  53 (2.1)  16 (1.6) 
Missing 3,868 (21.7)  1,118 (23.2)  1,004 (20.2)  853 (23.2)  692 (21.8)  201 (17.1) 
Median (IQR) cells/µl 137 (67.0 –199.0)  126(62-185)  133 (63-194)  142 (68-205)  152 (73-231)  148 (82-212) 
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 Table 1. Continues. 
 
WHO stage, number (%)                  
1 1,937 (10.9)  597 (12.4)  493 (9.9)  386 (10.5)  337 (10.7)  124 (10.6) 
2 3,117 (17.6)  922 (19.2)  837 (16.9)  600 (16.4)  572 (18.2)  185 (15.8) 
3 10,451 (58.9)  2,783 (57.8)  2,937 (59.4)  1811 (57.5)  1811 (57.5)  747 (63.8) 
4 2,242 (12.6)  513 (10.7)  677 (13.7)  508 (13.9)  428 (13.6)  116 (9.9) 
Missing 70 (0.39)  8 (0.2)  21 (0.4)  7 (0.2)  30 (0.9)  4 (0.3) 
 
 
 
 
 
Figure 2.Trend of CD4 cell count across the cohort. Test for trend shows df 12 p value <0.001. Those 
initiating ART with CD4 count less than 200 cell/mm3 were decreasing across the cohort, while those 
initiating ART with CD4 cell/mm3 were increasing across cohort. However those with ≥350 CD4 cell/mm3 
were slightly increasing with time. 
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Table 2. Mortality rates by potential baseline risk factors. 
 
Variable Category Number of people Death PYAR 
Mortality rates/1000 
PYAR (95% CI) P value** 
Overall  17,813 462 25.9 17.8 (16.2-19.5)  
Sex 
Male 7109 239 10.9 23.7 (20.9, 26.9) 
<0.001 
Female 10708 223 15.9 14.4 (12.3, 26.9) 
       
Age, years 
15-29 3558 89 4.91 18.1 (14.7, 22.3) 
0.75 
30-39 7206 189 10.50 17.9 (15.6, 20.8) 
40-49 4435 106 6.64 15.9 (13.2, 19.3) 
50+ 2455 69 3.68 18.8 (14.8, 23.8) 
       
Marital status 
Single 1940 59 2.18 27.1 (20.9, 34.9) 
0.15 
Married/Cohabiting 7099 190 8.65 21.9 (19.1, 25.3) 
Divorced/separated 1080 43 1.36 31.4 (23.3, 42.4) 
Widow 1928 56 2.52 22.2 (17.1, 28.9) 
       
Functional status 
Ambulatory 784 59 0.47 79.5 (57.6, 109.7) 
<0.001 Bedridden 177 190 0.21 74.8 (45.8, 122.1) 
Working 12,449 43 15.89 20.0 (17.9, 22.3) 
       
Weight, kg 
<45 3017 111 2.16 51.3 (42.6, 61.8) 
<0.001 45-55 80,006 157 9.16 16.3 (16.9, 19.1) 
>56 6247 111 13.42 8.3 (6.9, 9.9) 
       
CD4 cell counts, cells/µl 
<50 2682 124 3.57 34.8 (29.1, 41.4) 
<0.001 
50-199 7812 180 11.58 15.5 (13.4, 17.9) 
200-349 2852 60 3.99 15.0 (11.7, 19.3) 
350-499 417 16 0.50 31.9 (19.6, 52.2) 
>500 186 4 0.21 19.4 (7.3, 51.8) 
       
WHO stage 
1 1937 20 3.05 6.6 (4.2, 10.2) 
<0.001 
2 3117 49 4.90 9.9 (7.6, 713.2) 
3 10,451 298 15.14 19.7 (17.6, 22.0) 
4 2242 94 2.78 33.8 (27.6, 41.3) 
 
PYAR: person-years at risk; MR: mortality rate; CI: confidence interval, **p value from log-rank test. 
 
 
 
collected before the massive expansion of ART in 
Tanzania that has accompanied the new WHO guidelines 
and the 90-90-90 goals. While our data suggest 
programme performance comparable to that seen during 
the same period in Papua Guinea and Nigeria (Gray et 
al., 2011; Onoh, 2010) and while Tanzania has 
decentralised ART care to lower-level health facilities, 
which should theoretically improve access, our data 
suggest significant challenges in diagnosing, initiating 
and retaining patients on ART. Nonetheless, progress is 
evident. In Mbeya between 2009 and 2011 there was a 
50% increase in the number of ART-eligible patients who 
initiated treatment. Our study has also shown that in this 
region those initiating ART were doing so at an 
increasingly higher CD4 count as the programme 
progressed over the fourth-year (NACP, 2010).  
Using routine data to evaluate regional programmes is 
sustainable and realistic. Unlike clinical trials, which are 
designed to address proof of concept issues, integrating 
operational research utilising data collected routinely from 
standard government clinics has the potential to give a 
real picture of what is happening on the ground. The 
scale up of the computerised system across the country 
should make the system more timely and less arduous. 
However, the considerable amounts of missing data we 
found in our study support other studies in suggesting 
that the process needs reviewing and careful monitoring 
(Somi et al., 2012; Commission THEP, nd; Somi et al., 
2011). For instance, in our study it was not possible to 
calculate or utilise body mass index (an important metric 
to monitor trends and progress of patients on ART) given 
that height was consistently omitted in the registers.  
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 Table 3. Factors associated with mortality. 
 
Factor Level N Mortality rates Unadjusted HR * (95% CI) 
Adjusted HR * 
(95% CI) Adjusted p value 
Sex 
Male 7109 23.7 Referent Referent  
Female 10708 14.4 0.61 (0.51, 0.73) 0.47 (0.35, 0.62) <0.001 
       
Age, years 
15-29 3558 18.13 Referent Referent  
30-39 7206 15.61 1.03 (0.79, 1.31) 0.9 (0.62, 1.29) 0.62 
40-49 4435 13.21 0.93 (0.69, 1.23) 0.82 (0.59, 1.14) 0.241 
>50 2455 14.82 1.09 (0.79, 1.49) 1.01 (0.69, 1.49) 0.941 
       
Weight, kg 
<45 3017 51.3 4.68 (3.59, 6.1) 5.93 (4.23, 8.33) <0.001 
45-55 80,006 16.3 1.77 (1.39, 2.26) 1.6 (1.16, 2.21) 0.004 
>55 6247 8.3 Referent Referent  
       
WHO stage 
1 1937 6.6 Referent Referent  
2 3117 9.9 1.53 (0.91, 2.58) 1.38 (0.61, 3.10) 0.441 
3 10,451 19.7 2.89 (1.84, 4.54) 2.15 (1.05, 4.39) 0.036 
4 2242 33.8 4.50 (2.78, 7.29) 2.97 (1.39, 6.37) 0.005 
       
CD4 cell count, cells/µl 
<50 2682 34.8 Referent Referent  
50-199 7812 15.5 0.47 (0.38, 0.59) 0.75 (0.55, 1.01) 0.06 
200-349 2852 15.0 0.44 (0.33, 0.60) 0.51 (0.34, 0.78) 0.002 
350-499 417 31.9 0.87 (0.52, 1.47) 0.49 (0.19, 1.21) 0.12 
>500 186 19.4 0.50 (0.19, 1.36) 0.51 (0.12, 2.08) 0.34 
 
 *Hazard Ratio; CI confidence interval. 
 
 
 
Our study describes factors associated with mortality in 
Mbeya, which are comparable to those found in other 
African programmes (Biadgilign et al., 2012; Lawn et al., 
2008; Barth et al., 2011) with the majority of deaths 
occurring in the first 6 months after ART initiation 
(Amuron et al., 2011; Stewart et al., 2012; Bussmann et 
al., 2008). It is generally accepted that any improvements 
in mortality are likely to come from, amongst other things, 
more timely ART initiation (Johannessen et al., 2008). 
Historically, patients in Africa presented for ART once 
they developed advanced symptomatic disease with 
dangerously low CD4 counts (Johannessen et al., 2008; 
Orrell et al., 2011). We found that, whilst this is still often 
the case, the situation is changing. Data from Mbeya 
show a significant positive trend from 2008 to 2012 in the 
starting of ART at increasingly higher CD4 counts. 
However the median of 137 cells/µl during this period 
was still far below the then WHO recommended threshold 
for initiating ART at <350 cells/µl (WHO 2010) and still 
low for the country which, in 2009, had a median CD4 
count at ART initiation of 155 cells/µl (NACP, 2012). The 
high rates of loss to follow up in this study were seen in 
many others (Togun et al., 2011; Mossdorf et al., 2011). 
The challenge involved in minimising loss to follow up is 
significant given that as the CTC system currently stands 
it is not possible to track those that no-longer report for 
treatment.  
We recognise that our study has a number of important 
limitations. First, the patient records were often 
incomplete, particularly with regard to recording of height, 
CD4 cell counts, marital status, and functional status; 
therefore, the association of these variables with mortality 
may be underestimated. Similarly, some treatment 
outcomes recorded as ‘lost to follow up’ are most likely 
deaths, thereby underestimating mortality in this study. A 
study of tracing ART patients lost to follow up in South 
Africa found that 48% of patients who were recorded as 
lost to follow up were actually dead, 25% had relocated to 
other clinics, 10.5% were hospitalised and 4.6% had 
stopped medication after feeling well (Dalal et al., 2008). 
Despite these limitations, our study highlights important 
areas of focus for the monitoring and evaluation of the 
system. In addition to this further emphasis needs to be 
placed in Mbeya region and most probably across the 
country on strategies to increase the timely diagnosis of 
HIV infection and initiation of ART at higher CD4 counts; 
this will require expanded HIV testing, further 
decentralisation of CTC sites and in reducing out of 
pocket patient costs to facilitate improved access service. 
 
 
Conclusion 
 
Poor  data  quality,  documentation  and  reporting  within  
 
 
 
 
both the computerised and paper-based patient record 
systems limit the utility of the data for the purpose of 
programme evaluation and planning. From the data 
collected we conclude that whilst positive trends exist, 
further emphasis is needed on strategies to increase the 
timely initiation of ART at higher CD4 counts and to 
improve retention in care. We emphasise the need for an 
improved monitoring system to track those enrolling, 
initiating and dropping out of the system. 
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